Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANIEL BECKER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1881741775
CMS profile
221106
Location
LUTHERVILLE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$280,742.36

558 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 9 of 12; records 401–450 of 558 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANIEL BECKER

NPI 1881741775 · CMS profile ID 221106

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

LUTHERVILLE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 9 of 12; records 401–450 of 558 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1881741775?year=2022&recipient=provider&page=9#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANIEL BECKER, NPI 1881741775, CMS profile ID 221106. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 9 of 12; records 401–450 of 558 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1881741775?year=2022&recipient=provider&page=9#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). DANIEL BECKER, NPI 1881741775, CMS profile ID 221106. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 9 of 12; records 401–450 of 558 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1881741775?year=2022&recipient=provider&page=9#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
DANIEL BECKER, NPI 1881741775, CMS profile ID 221106, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 9 of 12; records 401–450 of 558 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1881741775?year=2022&recipient=provider&page=9#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

558 matching records · $280,742.36 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 558 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 401–450 of 558.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $92.8204/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932494967 CMS
E.R. Squibb & Sons, L.L.C. $756.7304/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932494979 CMS
Alexion Pharmaceuticals, Inc. $23.2304/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914843815 CMS
Celgene Corporation $3.0704/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932494917 CMS
Janssen Pharmaceuticals, Inc $24.8004/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886374153 CMS
ABBVIE INC. $4.6904/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890582203 CMS
Avanir Pharmaceuticals, Inc. $15.1004/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 935939007 CMS
Genentech USA, Inc. $1,800.0004/12/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950678497 CMS
ABBVIE INC. $23.1904/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890582201 CMS
Teva Pharmaceuticals USA, Inc. $29.3804/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954483915 CMS
Biohaven Pharmaceutical Holding Company Ltd. $19.0504/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923536865 CMS
Celgene Corporation $97.2904/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932494885 CMS
Celgene Corporation $4.3204/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932494911 CMS
Novartis Pharmaceuticals Corporation $2.5004/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893524269 CMS
Celgene Corporation $87.3904/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932494881 CMS
Novartis Pharmaceuticals Corporation $122.2104/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893524243 CMS
ABBVIE INC. $15.1904/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890582197 CMS
ABBVIE INC. $12.6904/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890582199 CMS
GENZYME CORPORATION $81.3104/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938978653 CMS
Genentech USA, Inc. $119.5904/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950682299 CMS
Horizon Therapeutics plc $3,598.0004/05/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937592017 CMS
Horizon Therapeutics plc $1,621.5004/05/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937592019 CMS
Celgene Corporation $41.5604/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932494907 CMS
Janssen Pharmaceuticals, Inc $49.0604/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886374099 CMS
Janssen Pharmaceuticals, Inc $242.2304/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886374105 CMS
Biohaven Pharmaceutical Holding Company Ltd. $4.4404/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923536863 CMS
Celgene Corporation $55.9104/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932494879 CMS
Celgene Corporation $44.9204/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932494883 CMS
Janssen Pharmaceuticals, Inc $2,860.0003/28/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886374093 CMS
Amgen Inc. $26.3303/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939304689 CMS
Celgene Corporation $3.8103/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932494913 CMS
ABBVIE INC. $10.2903/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890582193 CMS
ABBVIE INC. $18.9603/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890582195 CMS
Horizon Therapeutics plc $7.3603/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937592015 CMS
Janssen Pharmaceuticals, Inc $22.2403/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886374337 CMS
Banner Life Sciences, LLC $15.4203/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957718239 CMS
Horizon Therapeutics plc $105.5703/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937592013 CMS
ABBVIE INC. $14.3203/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890582191 CMS
Genentech USA, Inc. $24.3503/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950793105 CMS
Horizon Therapeutics plc $3.3003/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937592009 CMS
Horizon Therapeutics plc $124.9903/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937592011 CMS
Avanir Pharmaceuticals, Inc. $16.0503/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 935930087 CMS
E.R. Squibb & Sons, L.L.C. $4,030.0003/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932494895 CMS
E.R. Squibb & Sons, L.L.C. $409.5003/15/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932494899 CMS
Horizon Therapeutics plc $126.6503/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937592007 CMS
Novartis Pharmaceuticals Corporation $9.1403/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893524267 CMS
Celgene Corporation $8.6903/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932494905 CMS
EMD Serono, Inc. $25.1603/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941500477 CMS
Janssen Pharmaceuticals, Inc $1,100.0003/14/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886374073 CMS
EMD Serono, Inc. $31.8903/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941499635 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $438,522.97 468
PY2020 $122,356.95 227
PY2021 $134,302.91 343
PY2022 $280,742.36 558
PY2023 $215,638.63 397
PY2024 $226,720.09 418
PY2025 $164,667.41 362

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $94,506.85 153
PY2024 Recipient $2,630.78 14
PY2024 Principal investigator $163,714.97 178
PY2023 Principal investigator $286,926.29 154
PY2022 Principal investigator $685,048.30 34
PY2021 Principal investigator $707,002.02 33
PY2020 Principal investigator $648,302.85 44
PY2019 Recipient $1,087.63 9
PY2019 Principal investigator $61,903.76 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

153 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $80.00 11/14/2025 Non-covered Recipient Entity
International Neurorehabilitation Institute
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226134252
Principal investigator 1 Roche Products Limited $235.00 09/25/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616872
Principal investigator 1 Roche Products Limited $235.00 09/25/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616875
Principal investigator 1 Roche Products Limited $211.50 09/25/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616878
Principal investigator 1 Roche Products Limited $235.00 09/25/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616883
Principal investigator 1 Roche Products Limited $235.00 09/25/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616886
Principal investigator 1 Roche Products Limited $235.00 09/25/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616889
Principal investigator 1 Roche Products Limited $235.00 09/25/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616893
Principal investigator 1 Roche Products Limited $235.00 09/25/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616897
Principal investigator 1 Genentech, Inc. $4,457.00 09/19/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211616916
Principal investigator 1 Genentech, Inc. $1,277.00 09/18/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211616912
Principal investigator 1 GENZYME CORPORATION $5,400.00 09/17/2025 Non-covered Recipient Entity
Internationall Neuro Rehabilitation Institute
A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1226147395
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616550
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616554
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616559
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616563
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616566
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616571
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616574
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616579
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616584
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616587
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616592
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616595
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616600
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616604
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616608
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616613
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616620
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616624
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616628
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616632
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616636
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616639
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616644
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616647
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616652
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616656
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616660
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616664
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616669
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616673
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616677
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616681
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616686
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616690
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616694
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616699
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616703
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616707
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616711
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616717
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616721
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616723
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616727
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616731
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616734
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616739
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616742
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616747
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616752
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616757
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616761
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616765
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616768
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616772
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616776
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616780
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616788
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616792
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616797
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616800
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616804
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616808
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616812
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616816
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616820
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616825
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616829
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616834
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616837
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616841
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616844
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616849
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616854
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616858
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616862
Principal investigator 1 Roche Products Limited $235.00 06/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616868
Principal investigator 1 Genentech, Inc. $4,885.90 06/10/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211616900
Principal investigator 1 GENZYME CORPORATION $13,050.00 06/09/2025 Non-covered Recipient Entity
Internationall Neuro Rehabilitation Institute
A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1226094053
Principal investigator 1 Genentech, Inc. $26,455.00 04/15/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211616903
Principal investigator 1 Genentech, Inc. $4,850.45 04/03/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211616908
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616310
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616313
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616315
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616320
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616323
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616331
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616335
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616339
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616344
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616348
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616353
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616358
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616372
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616376
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616381
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616384
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616387
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616389
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616396
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616400
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616405
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616410
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616415
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616419
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616423
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616426
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616430
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616434
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616438
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616445
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616449
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616453
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616461
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616465
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616469
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616472
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616477
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616491
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616495
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616499
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616503
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616508
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616512
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616519
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616523
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616526
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616533
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616537
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616546
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616317
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616327
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616365
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616369
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616392
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616442
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616458
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616481
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616485
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616515
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616530
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
INTERNATIONAL NEUROREHABILITATION INSTITUTE
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616542